Clinical trials
4 active studies led by Actelion, of 143 in all
Source: ClinicalTrials.gov, Studies with Actelion (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public records show Actelion in 3 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Actelion or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
Source: Wikidata, Company record Q343217. Retrieved 13 Nov 2026.
4 active studies led by Actelion, of 143 in all
Source: ClinicalTrials.gov, Studies with Actelion (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
8 approvals with a product on the US market
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
Studies Actelion leads, by the year they started and their phase
Source: ClinicalTrials.gov, Studies with Actelion or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets we cover where free public records show Actelion: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Actelion is in.
Stories on the topics Actelion works in.
Omega-3 supplements are hugely popular. Big trials give mixed answers on whether they protect the heart.
Read
Cardiovascular disease is the world's leading cause of death, and stroke caused 11.9 million new cases in…
Read
Keeping the airway open is the first step in saving a life. More than half of deaths in low- and…
Read